212 related articles for article (PubMed ID: 18754841)
1. Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies?
Golder S; Loke YK
Br J Clin Pharmacol; 2008 Dec; 66(6):767-73. PubMed ID: 18754841
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical industry sponsorship and research outcome and quality: systematic review.
Lexchin J; Bero LA; Djulbegovic B; Clark O
BMJ; 2003 May; 326(7400):1167-70. PubMed ID: 12775614
[TBL] [Abstract][Full Text] [Related]
3. Outcome reporting among drug trials registered in ClinicalTrials.gov.
Bourgeois FT; Murthy S; Mandl KD
Ann Intern Med; 2010 Aug; 153(3):158-66. PubMed ID: 20679560
[TBL] [Abstract][Full Text] [Related]
4. Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis.
Khan NA; Lombeida JI; Singh M; Spencer HJ; Torralba KD
Arthritis Rheum; 2012 Jul; 64(7):2059-67. PubMed ID: 22275179
[TBL] [Abstract][Full Text] [Related]
5. Unpublished data can be of value in systematic reviews of adverse effects: methodological overview.
Golder S; Loke YK; Bland M
J Clin Epidemiol; 2010 Oct; 63(10):1071-81. PubMed ID: 20457510
[TBL] [Abstract][Full Text] [Related]
6. Sponsors' participation in conduct and reporting of industry trials: a descriptive study.
Lundh A; Krogsbøll LT; Gøtzsche PC
Trials; 2012 Aug; 13():146. PubMed ID: 22920226
[TBL] [Abstract][Full Text] [Related]
7. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?
Als-Nielsen B; Chen W; Gluud C; Kjaergard LL
JAMA; 2003 Aug; 290(7):921-8. PubMed ID: 12928469
[TBL] [Abstract][Full Text] [Related]
8. Industry sponsorship and publication bias among animal studies evaluating the effects of statins on atherosclerosis and bone outcomes: a meta-analysis.
Anglemyer AT; Krauth D; Bero L
BMC Med Res Methodol; 2015 Mar; 15():12. PubMed ID: 25880564
[TBL] [Abstract][Full Text] [Related]
9. Association between funding source, methodological quality and research outcomes in randomized controlled trials of synbiotics, probiotics and prebiotics added to infant formula: a systematic review.
Mugambi MN; Musekiwa A; Lombard M; Young T; Blaauw R
BMC Med Res Methodol; 2013 Nov; 13():137. PubMed ID: 24219082
[TBL] [Abstract][Full Text] [Related]
10. Industry sponsorship and research outcome.
Lundh A; Sismondo S; Lexchin J; Busuioc OA; Bero L
Cochrane Database Syst Rev; 2012 Dec; 12():MR000033. PubMed ID: 23235689
[TBL] [Abstract][Full Text] [Related]
11. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
12. Association between pacifier use and breast-feeding, sudden infant death syndrome, infection and dental malocclusion.
Callaghan A; Kendall G; Lock C; Mahony A; Payne J; Verrier L
JBI Libr Syst Rev; 2005; 3(6):1-33. PubMed ID: 27819973
[TBL] [Abstract][Full Text] [Related]
13. Industry funding of patient and health consumer organisations: systematic review with meta-analysis.
Fabbri A; Parker L; Colombo C; Mosconi P; Barbara G; Frattaruolo MP; Lau E; Kroeger CM; Lunny C; Salzwedel DM; Mintzes B
BMJ; 2020 Jan; 368():l6925. PubMed ID: 31969320
[TBL] [Abstract][Full Text] [Related]
14. Reporting of Adverse Events in Published and Unpublished Studies of Health Care Interventions: A Systematic Review.
Golder S; Loke YK; Wright K; Norman G
PLoS Med; 2016 Sep; 13(9):e1002127. PubMed ID: 27649528
[TBL] [Abstract][Full Text] [Related]
15. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.
Heres S; Davis J; Maino K; Jetzinger E; Kissling W; Leucht S
Am J Psychiatry; 2006 Feb; 163(2):185-94. PubMed ID: 16449469
[TBL] [Abstract][Full Text] [Related]
16. Association of industry sponsorship to published outcomes in gastrointestinal clinical research.
Brown A; Kraft D; Schmitz SM; Sharpless V; Martin C; Shah R; Shaheen NJ
Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1445-51. PubMed ID: 17101295
[TBL] [Abstract][Full Text] [Related]
17. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
18. Sponsorship-related outcome selection bias in published economic studies of triptans: systematic review.
Peura PK; Martikainen JA; Purmonen TT; Turunen JH
Med Decis Making; 2012; 32(2):237-45. PubMed ID: 21490308
[TBL] [Abstract][Full Text] [Related]
19. Does the funding source influence the results in economic evaluations? A case study in bisphosphonates for the treatment of osteoporosis.
Fleurence RL; Spackman DE; Hollenbeak C
Pharmacoeconomics; 2010; 28(4):295-306. PubMed ID: 20222753
[TBL] [Abstract][Full Text] [Related]
20. Interactions between physicians and the pharmaceutical industry: what does the literature say?
Lexchin J
CMAJ; 1993 Nov; 149(10):1401-7. PubMed ID: 8221424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
